<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37143081</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Opinion: more mouse models and more translation needed for ALS.</ArticleTitle><Pagination><StartPage>30</StartPage><MedlinePgn>30</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-023-00619-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a complex disorder most of which is 'sporadic' of unknown origin but approximately 10% is familial, arising from single mutations in any of more than 30 genes. Thus, there are more than 30 familial ALS subtypes, with different, often unknown, molecular pathologies leading to a complex constellation of clinical phenotypes. We have mouse models for many genetic forms of the disorder, but these do not, on their own, necessarily show us the key pathological pathways at work in human patients. To date, we have no models for the 90% of ALS that is 'sporadic'. Potential therapies have been developed mainly using a limited set of mouse models, and through lack of alternatives, in the past these have been tested on patients regardless of aetiology. Cancer researchers have undertaken therapy development with similar challenges; they have responded by producing complex mouse models that have transformed understanding of pathological processes, and they have implemented patient stratification in multi-centre trials, leading to the effective translation of basic research findings to the clinic. ALS researchers have successfully adopted this combined approach, and now to increase our understanding of key disease pathologies, and our rate of progress for moving from mouse models to mechanism to ALS therapies we need more, innovative, complex mouse models to address specific questions.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Elizabeth M C</ForeName><Initials>EMC</Initials><Identifier Source="ORCID">0000-0003-2850-9936</Identifier><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK. elizabeth.fisher@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK. elizabeth.fisher@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greensmith</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavo</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, WC1E 6BT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orrell</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>MRC Prion Unit at UCL, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arozena</LastName><ForeName>Abraham Acevedo</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Research Unit, Hospital Universitario de Canarias, ITB-ULL and CIBERNED, La Laguna, 38320, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S005021/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107116/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>223022/Z/21/</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Mouse models</Keyword><Keyword MajorTopicYN="N">Patient stratification</Keyword><Keyword MajorTopicYN="N">Translation</Keyword></KeywordList><CoiStatement>Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37143081</ArticleId><ArticleId IdType="pmc">PMC10161557</ArticleId><ArticleId IdType="doi">10.1186/s13024-023-00619-2</ArticleId><ArticleId IdType="pii">10.1186/s13024-023-00619-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman EL, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363&#x2013;80. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta RC, Traynor R, Chio BJ. Unraveling the complex interplay between genes, environment, and climate in ALS. eBioMedicine. 2022;75:103795. doi: 10.1016/j.ebiom.2021.103795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103795</ArticleId><ArticleId IdType="pmc">PMC8728044</ArticleId><ArticleId IdType="pubmed">34974309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, et al. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745&#x2013;51. doi: 10.1111/j.1468-1331.2009.02586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02586.x</ArticleId><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira Santos M, et al. Clinical characteristics in amyotrophic lateral sclerosis with Sub-Saharan Africa ancestry - A portuguese hospital-based cohort study. Clin Neurol Neurosurg. 2023;227:107674. doi: 10.1016/j.clineuro.2023.107674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2023.107674</ArticleId><ArticleId IdType="pubmed">36933404</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253(12):1642&#x2013;3. doi: 10.1007/s00415-006-0195-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0195-y</ArticleId><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):485&#x2013;95. doi: 10.1080/21678421.2020.1779298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779298</ArticleId><ArticleId IdType="pubmed">32583689</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636&#x2013;48. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros BD, et al. Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics. 2022;19(4):1145&#x2013;58. doi: 10.1007/s13311-022-01247-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01247-2</ArticleId><ArticleId IdType="pmc">PMC9587169</ArticleId><ArticleId IdType="pubmed">35653060</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104&#x2013;16. doi: 10.1038/s41591-021-01615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom KE, Brown RH. Approaches to Gene Modulation Therapy for ALS. Neurotherapeutics. 2022;19(4):1159&#x2013;79. doi: 10.1007/s13311-022-01285-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01285-w</ArticleId><ArticleId IdType="pmc">PMC9587165</ArticleId><ArticleId IdType="pubmed">36068427</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;19. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2022;28(1):117&#x2013;24. doi: 10.1038/s41591-021-01557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;90. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;30. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131&#x2013;7. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughn MW, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140&#x2013;9. doi: 10.1126/science.abq5622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq5622</ArticleId><ArticleId IdType="pmc">PMC10148063</ArticleId><ArticleId IdType="pubmed">36927019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfes L, et al. Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Commun. 2021;3(3):fcab157. doi: 10.1093/braincomms/fcab157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab157</ArticleId><ArticleId IdType="pmc">PMC8363480</ArticleId><ArticleId IdType="pubmed">34405141</ArticleId></ArticleIdList></Reference><Reference><Citation>Campisi L, et al. Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4. Nature. 2022;606(7916):945&#x2013;52. doi: 10.1038/s41586-022-04844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04844-5</ArticleId><ArticleId IdType="pmc">PMC10089623</ArticleId><ArticleId IdType="pubmed">35732742</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz O, Schroth J, Tree T, Turner MR, Shaw PJ, Henson SM, Malaspina A. Senescent-like blood lymphocytes and disease progression in amyotrophic lateral sclerosis. Neurology: Neuroimmunology &amp; Neuroinflammation; 2022. p. e200042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9673751</ArticleId><ArticleId IdType="pubmed">36323511</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492&#x2013;506. doi: 10.1038/s41422-020-0332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0332-7</ArticleId><ArticleId IdType="pmc">PMC7264227</ArticleId><ArticleId IdType="pubmed">32433595</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;80. doi: 10.1038/s41586-019-1443-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn Superoxide-Dismutase Gene are Associated with familial amyotrophic-lateral-sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772&#x2013;5. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;72. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;11. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F, et al. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech. 2019;12(1):dmm037424. doi: 10.1242/dmm.037424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.037424</ArticleId><ArticleId IdType="pmc">PMC6361152</ArticleId><ArticleId IdType="pubmed">30626575</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd TW, Petrucelli L. Modelling amyotrophic lateral sclerosis in rodents. Nat Rev Neurosci. 2022;23(4):231&#x2013;51. doi: 10.1038/s41583-022-00564-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-022-00564-x</ArticleId><ArticleId IdType="pubmed">35260846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. PLoS ONE. 2022;17(2):e0255710. doi: 10.1371/journal.pone.0255710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255710</ArticleId><ArticleId IdType="pmc">PMC8812852</ArticleId><ArticleId IdType="pubmed">35113871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37(11):e98684. doi: 10.15252/embj.201798684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;63. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, et al. Coexistence of perseveration and apathy in the TDP-43(Q331K) knock-in mouse model of ALS-FTD. Transl Psychiatry. 2020;10(1):377. doi: 10.1038/s41398-020-01078-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01078-9</ArticleId><ArticleId IdType="pmc">PMC7643138</ArticleId><ArticleId IdType="pubmed">33149110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage Dose-Dependent Motor Neuron Degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 2019;26(2):364&#x2013;73. doi: 10.1016/j.celrep.2018.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SL, et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;8(1):3. doi: 10.1186/s40478-020-0881-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0881-5</ArticleId><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x2018;FUSDelta14&#x2019; knockin mice. Brain. 2017;140(11):2797&#x2013;805. doi: 10.1093/brain/awx248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId><ArticleId IdType="pmc">PMC5841203</ArticleId><ArticleId IdType="pubmed">29053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A, et al. Generation and analysis of innovative genomically humanized knockin SOD1, TARDBP (TDP-43), and FUS mouse models. iScience. 2021;24(12):103463. doi: 10.1016/j.isci.2021.103463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103463</ArticleId><ArticleId IdType="pmc">PMC8710557</ArticleId><ArticleId IdType="pubmed">34988393</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077&#x2013;97. doi: 10.15252/embj.201592559.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201592559</ArticleId><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, et al. Humanising the mouse genome piece by piece. Nat Commun. 2019;10(1):1845. doi: 10.1038/s41467-019-09716-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09716-7</ArticleId><ArticleId IdType="pmc">PMC6478830</ArticleId><ArticleId IdType="pubmed">31015419</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair RR, et al. Uses for humanised mouse models in precision medicine for neurodegenerative disease. Mamm Genome. 2019;30(7&#x2013;8):173&#x2013;91. doi: 10.1007/s00335-019-09807-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-019-09807-2</ArticleId><ArticleId IdType="pmc">PMC6759662</ArticleId><ArticleId IdType="pubmed">31203387</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo-Arozena A, et al. A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech. 2011;4(5):686&#x2013;700. doi: 10.1242/dmm.007237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.007237</ArticleId><ArticleId IdType="pmc">PMC3180233</ArticleId><ArticleId IdType="pubmed">21540242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, et al. Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain. 2023;146(1):13&#x2013;9. doi: 10.1093/brain/awac306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac306</ArticleId><ArticleId IdType="pubmed">36004509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3(4):fcab242. doi: 10.1093/braincomms/fcab242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahdeo S, Goldstein DB. Translating amyotrophic lateral sclerosis genes into drug development leads. Nat Genet. 2021;53(12):1624&#x2013;6. doi: 10.1038/s41588-021-00981-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00981-1</ArticleId><ArticleId IdType="pubmed">34873336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;5. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan C, et al. Whole-genome sequencing reveals that variants in the Interleukin 18 receptor accessory protein 3&#x2019;UTR protect against ALS. Nat Neurosci. 2022;25(4):433&#x2013;45. doi: 10.1038/s41593-022-01040-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01040-6</ArticleId><ArticleId IdType="pubmed">35361972</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610&#x2013;26. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, et al. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127(3):441&#x2013;50. doi: 10.1007/s00401-013-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoshima Y, Takahashi H. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis. Neuropathology. 2014;34(1):77&#x2013;82. doi: 10.1111/neup.12053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12053</ArticleId><ArticleId IdType="pubmed">23889603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, et al. Heavy metal neurotoxicants induce ALS-Linked TDP-43 Pathology. Toxicol Sci. 2019;167(1):105&#x2013;15. doi: 10.1093/toxsci/kfy267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfy267</ArticleId><ArticleId IdType="pmc">PMC6317426</ArticleId><ArticleId IdType="pubmed">30371865</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammisetty SS, et al. Targeting TDP-43 Pathology alleviates cognitive and motor deficits caused by chronic cerebral hypoperfusion. Neurotherapeutics. 2021;18(2):1095&#x2013;112. doi: 10.1007/s13311-021-01015-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01015-8</ArticleId><ArticleId IdType="pmc">PMC8423945</ArticleId><ArticleId IdType="pubmed">33786804</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371(6529):eabb4309. doi: 10.1126/science.abb4309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4309</ArticleId><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110(8):E736&#x2013;45. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9(1):4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD. Neurobiol Dis. 2023;179:106050. doi: 10.1016/j.nbd.2023.106050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2023.106050</ArticleId><ArticleId IdType="pubmed">36809847</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726&#x2013;38. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak AN, Djukic S, Kadlecova M, Braunstein TH, Jensen DB, Meehan CF. Cytoplasmic TDP-43 accumulation drives changes in C-bouton number and size in a mouse model of sporadic Amyotrophic Lateral Sclerosis. Mol Cell Neurosci. 2023;125:103840. doi: 10.1016/j.mcn.2023.103840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2023.103840</ArticleId><ArticleId IdType="pubmed">36921783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Rivera FJ et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci USA. 2021;118(23).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201929</ArticleId><ArticleId IdType="pubmed">34074758</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323&#x2013;34. doi: 10.1016/j.cell.2006.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.12.007</ArticleId><ArticleId IdType="pubmed">17182091</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656&#x2013;60. doi: 10.1038/nature05529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05529</ArticleId><ArticleId IdType="pmc">PMC4601097</ArticleId><ArticleId IdType="pubmed">17251933</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila MR, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010;468(7323):567&#x2013;71. doi: 10.1038/nature09526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09526</ArticleId><ArticleId IdType="pmc">PMC3011233</ArticleId><ArticleId IdType="pubmed">21107427</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JPt, et al. Alpha-ketoglutarate links p53 to cell fate during tumour suppression. Nature. 2019;573(7775):595&#x2013;9. doi: 10.1038/s41586-019-1577-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1577-5</ArticleId><ArticleId IdType="pmc">PMC6830448</ArticleId><ArticleId IdType="pubmed">31534224</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan DJ, et al. NOTUM from apc-mutant cells biases clonal competition to initiate cancer. Nature. 2021;594(7863):430&#x2013;5. doi: 10.1038/s41586-021-03525-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03525-z</ArticleId><ArticleId IdType="pubmed">34079124</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger AM, et al. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022;607(7917):149&#x2013;55. doi: 10.1038/s41586-022-04839-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04839-2</ArticleId><ArticleId IdType="pmc">PMC9945857</ArticleId><ArticleId IdType="pubmed">35705813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisahara S, et al. Possible somatic mosaicism of novel FUS variant in familial amyotrophic lateral sclerosis. Neurol Genet. 2021;7(1):e552. doi: 10.1212/NXG.0000000000000552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000552</ArticleId><ArticleId IdType="pmc">PMC8112850</ArticleId><ArticleId IdType="pubmed">33987464</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank SA. Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010;107:1725&#x2013;30. doi: 10.1073/pnas.0909343106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909343106</ArticleId><ArticleId IdType="pmc">PMC2868288</ArticleId><ArticleId IdType="pubmed">19805033</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108&#x2013;13. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher EM, et al. New approaches for modelling sporadic genetic disease in the mouse. Dis Model Mech. 2009;2(9&#x2013;10):446&#x2013;53. doi: 10.1242/dmm.001644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.001644</ArticleId><ArticleId IdType="pmc">PMC2737055</ArticleId><ArticleId IdType="pubmed">19726804</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29(12):3345&#x2013;58. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmaier SL, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12. doi: 10.1186/s12955-022-01919-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-01919-9</ArticleId><ArticleId IdType="pmc">PMC8781297</ArticleId><ArticleId IdType="pubmed">35062955</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I, et al. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci. 2021;24(11):1534&#x2013;41. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Adaptive platform trials to transform amyotrophic lateral sclerosis Therapy Development. Ann Neurol. 2022;91(2):165&#x2013;75. doi: 10.1002/ana.26285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26285</ArticleId><ArticleId IdType="pubmed">34935174</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv [Preprint]. 2023;2023:01.23.525202. 10.1101/2023.01.23.525202.&#xa0;</Citation></Reference><Reference><Citation>Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;18. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206&#x2013;16. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E, et al. Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):4478. doi: 10.1038/s41598-019-40632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40632-4</ArticleId><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2013;23. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4(1):fcac029. doi: 10.1093/braincomms/fcac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler. 2011;12(2):79&#x2013;86. doi: 10.3109/17482968.2010.550626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550626</ArticleId><ArticleId IdType="pubmed">21241159</ArticleId></ArticleIdList></Reference><Reference><Citation>Margotta C, et al. Immune-mediated myogenesis and acetylcholine receptor clustering promote a slow disease progression in ALS mouse models. Inflamm Regen. 2023;43(1):19. doi: 10.1186/s41232-023-00270-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-023-00270-w</ArticleId><ArticleId IdType="pmc">PMC9996869</ArticleId><ArticleId IdType="pubmed">36895050</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena GN, et al. Spinal cord metabolic signatures in models of fast- and slow-progressing SOD1(G93A) amyotrophic lateral sclerosis. Front Neurosci. 2019;13:1276. doi: 10.3389/fnins.2019.01276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01276</ArticleId><ArticleId IdType="pmc">PMC6914819</ArticleId><ArticleId IdType="pubmed">31920474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402&#x2013;5. doi: 10.1038/nm1021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1021</ArticleId><ArticleId IdType="pubmed">15034571</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565&#x2013;74. doi: 10.1212/WNL.0000000000004960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004960</ArticleId><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaiyachati BH, et al. LoxP-FRT trap (LOFT): a simple and flexible system for conventional and reversible gene targeting. BMC Biol. 2012;10:96. doi: 10.1186/1741-7007-10-96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7007-10-96</ArticleId><ArticleId IdType="pmc">PMC3529186</ArticleId><ArticleId IdType="pubmed">23198860</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles-Oteiza C, et al. Recombinase-based conditional and reversible gene regulation via XTR alleles. Nat Commun. 2015;6:8783. doi: 10.1038/ncomms9783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9783</ArticleId><ArticleId IdType="pmc">PMC4635517</ArticleId><ArticleId IdType="pubmed">26537451</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedemark-Margulies N, Trapani JG. Tools, methods, and applications for optophysiology in neuroscience. Front Mol Neurosci. 2013;6:18. doi: 10.3389/fnmol.2013.00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2013.00018</ArticleId><ArticleId IdType="pmc">PMC3713398</ArticleId><ArticleId IdType="pubmed">23882179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, et al. SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function. Neurobiol Dis. 2023;178:106022. doi: 10.1016/j.nbd.2023.106022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2023.106022</ArticleId><ArticleId IdType="pubmed">36716828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasal DN, Bendelac A. Multi-transcription factor reporter mice delineate early precursors to the ILC and LTi lineages. J Exp Med. 2021;218(2):e20200487. doi: 10.1084/jem.20200487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200487</ArticleId><ArticleId IdType="pmc">PMC7590509</ArticleId><ArticleId IdType="pubmed">33104170</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenstock S, et al. Fluc-EGFP reporter mice reveal differential alterations of neuronal proteostasis in aging and disease. EMBO J. 2021;40(19):e107260. doi: 10.15252/embj.2020107260.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020107260</ArticleId><ArticleId IdType="pmc">PMC8488555</ArticleId><ArticleId IdType="pubmed">34410010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlaschin JJ, et al. Promoting regeneration while blocking cell death preserves motor neuron function in a model of ALS. Brain. 2022 doi: 10.1093/brain/awac415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac415</ArticleId><ArticleId IdType="pubmed">36342754</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrayoz M, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29(3):632&#x2013;45. doi: 10.1038/s41591-022-02178-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02178-3</ArticleId><ArticleId IdType="pmc">PMC10033443</ArticleId><ArticleId IdType="pubmed">36928817</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, et al. Chronic BMAA exposure combined with TDP-43 mutation elicits motor neuron dysfunction phenotypes in mice. Neurobiol Aging. 2023;126:44&#x2013;57. doi: 10.1016/j.neurobiolaging.2023.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2023.02.010</ArticleId><ArticleId IdType="pubmed">36931113</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013;110(48):19555&#x2013;60. doi: 10.1073/pnas.1318268110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318268110</ArticleId><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Riquelme A, et al. Prion-like propagation of beta-amyloid aggregates in the absence of APP overexpression. Acta Neuropathol Commun. 2018;6(1):26. doi: 10.1186/s40478-018-0529-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0529-x</ArticleId><ArticleId IdType="pmc">PMC5883524</ArticleId><ArticleId IdType="pubmed">29615128</ArticleId></ArticleIdList></Reference><Reference><Citation>Purro SA, et al. Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone. Nature. 2018;564(7736):415&#x2013;9. doi: 10.1038/s41586-018-0790-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0790-y</ArticleId><ArticleId IdType="pmc">PMC6708408</ArticleId><ArticleId IdType="pubmed">30546139</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, et al. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262. doi: 10.3389/fnmol.2019.00262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00262</ArticleId><ArticleId IdType="pmc">PMC6838634</ArticleId><ArticleId IdType="pubmed">31736708</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017;40:189&#x2013;210. doi: 10.1146/annurev-neuro-072116-031153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539(7628):217&#x2013;26. doi: 10.1038/nature20415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20415</ArticleId><ArticleId IdType="pubmed">27830781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative Diseases. Annu Rev Neurosci. 2019;42:385&#x2013;406. doi: 10.1146/annurev-neuro-070918-050501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558&#x2013;67. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95&#x2013;119. doi: 10.1146/annurev.pathol.3.121806.154244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathol.3.121806.154244</ArticleId><ArticleId IdType="pubmed">20936938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallya K, et al. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188554. doi: 10.1016/j.bbcan.2021.188554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2021.188554</ArticleId><ArticleId IdType="pmc">PMC8570383</ArticleId><ArticleId IdType="pubmed">33945847</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiki Y, et al. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers (Basel) 2021;14(1):71. doi: 10.3390/cancers14010071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14010071</ArticleId><ArticleId IdType="pmc">PMC8750056</ArticleId><ArticleId IdType="pubmed">35008235</ArticleId></ArticleIdList></Reference><Reference><Citation>van Miltenburg MH, Jonkers J. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev. 2012;22(1):21&#x2013;7. doi: 10.1016/j.gde.2012.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2012.01.004</ArticleId><ArticleId IdType="pubmed">22321988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, et al. Motor Neuron Disease systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12(7):e064173. doi: 10.1136/bmjopen-2022-064173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-064173</ArticleId><ArticleId IdType="pmc">PMC9263927</ArticleId><ArticleId IdType="pubmed">35798516</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):496&#x2013;501. doi: 10.1080/21678421.2020.1788092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1788092</ArticleId><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>